Fig. 5: OTUDin3 inhibits the NSCLC growth in vivo.
From: Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer
A Photographic images of xenograft tumors from control and OTUDin3 treatment groups. Tumor-bearing mice were divided into 6 blocks according to tumor size, and then mice in each block were randomly assigned to different groups (Randomized block design). B The growth curves of xenograft tumors in each mouse are shown, the length and width of tumors were measured every other day. Randomized block design. Tumor volume was calculated by the formula: V = 0.5 × length × width2. C Tumor growth was significantly reduced in a dose-dependent manner by treatment with OTUDin3. The volumes of harvested xenograft tumors were measured. Randomized block design. Wilcoxon test. *p < 0.05. D The weights of harvested xenograft tumors were measured. Randomized block design. Wilcoxon test. *p < 0.05. E Representative immunohistochemical staining images of GRP78, Ki67 and Cleaved Caspase-3 in tumors from nude mice with or without OTUDin3 treatment. Scale bar, 50 µm. F Analysis of body weight during treatment of H1299 xenograft-bearing mice with OTUDin3. The data shown are mean ± SD, n = 6, Two-way ANOVA, ns = no significance. G Representative H&E staining images of hearts, livers, kidneys, lungs and spleens from nude mice with or without OTUDin3 treatment. Scale bar, 100 μm.
